Table 1

Ongoing clinical trials in endometrial cancer

Trial identifier	Disease characteristics in patient population	Treatment arms	Trial No
Primary adjuvant treatment
GY020	Stage I/II dMMR endometrioid tumours	Local radiation Local radiation and pembrolizumab	NCT04214067
RUBY	Advanced or recurrent disease	Carboplatin and paclitaxel, and dostarlimab → dostarlimab every 6 weeks up to 3 years Carboplatin and paclitaxel, and placebo → placebo	NCT03981796
GY018	Advanced or recurrent disease	Carboplatin and paclitaxel, and pembrolizumab → pembrolizumab every 3 weeks up to 5 years Carboplatin and paclitaxel, and placebo → placebo	NCT03914612
AtTEnd	Advanced or recurrent disease	Carboplatin and paclitaxel, and atezolizumab → atezolizumab every 3 weeks to disease progression Carboplatin and paclitaxel, and placebo → placebo	NCT03603184
GOG3053/KEYNOTE-B21/ENGOT-en11	Non-endometrioid stage I/II with myometrial invasion TP53 aberrant tumours Stage III/IV	Carboplatin and paclitaxel, and pembrolizumab → pembrolizumab, six cycles Carboplatin and paclitaxel, and placebo → placebo	NCT04634877
LEAP001	Advanced or recurrent disease	Carboplatin and paclitaxel Lenvatinib and pembrolizumab	NCT03884101
GOG3064	Advanced or recurrent disease with dMMR tumours	Carboplatin and paclitaxel Pembrolizumab	NCT05173987
Maintenance treatment
DUO-E	Advanced or recurrent disease	Carboplatin and paclitaxel, and placebo → placebo Carboplatin and paclitaxel, and durvalumab → durvalumab every 4 weeks and placebo Carboplatin and paclitaxel, and durvalumab → durvaulmab every 4 weeks and olaparib	NCT04269200
PARPI maintenance	Advanced or recurrent disease	Rucaparib until disease progression Placebo	NCT03617679
SIENDO	Stage IV or first relapse	Selinexor until disease progression Placebo	NCT03555422
Recurrent disease
GY012	Recurrent	Cediranib Olaparib Olaparib and cediranib Olaparib and capivasertib Olaparib and durvalumab Cediranib and durvalumab	NCT03660826
GOG3038/PODIUM/ENGOT-en12	Advanced or recurrent disease	No previous treatment involving checkpoint inhibitors MSI-H: retifanliimab; dMMR or POLE: retifanlimab Previous treatment involving checkpoint inhibitors Unselected: retifanlimab and epacadostat Fibroblast growth factor receptor 1/2/3 mutation: retifanlimab and pemgatinib	NCT04463771
ADAGIO	Recurrent or persistent uterine serous carcinomas	Adavosertib	NCT04590248
GOG3039	Advanced or recurrent	Abemaciclib and letrazole	NCT04393285
Solely molecularly driven treatments
PORTEC-4a	Stage I/II, high intermediate risk	Favourable disease: observation Intermediate: vaginal brachytherapy Unfavourable: external beam radiation	NCT03469674
TAPER	Stage I/II, high intermediate risk, POLE and p53 wild type	No treatment	NCT04705649
RAINBO	Stage I-IV	TP53 Chemotherapy Chemotherapy and olaparib dMMR Radiation Radiation and durvalumab No specific molecular profile Chemoradiation Radiation and megestrol acetate POLE mutation Observation	NCT05255653

Table does not include all ongoing trials, because more than 900 clinical trials for endometrial cancer were listed on ClinicalTrials.gov at time of publication. Arrows indicate the second stage of the trial. dMMR=mismatch repair deficient tumours; MSI-H=microsatellite instability, hypermutated; POLE=DNA polymerase ε; TP53=tumour protein p53; PARPI=poly-ADP ribose polymerase inhibitors.